Loading…
Hosted by Norstella · EN · 8 episodes
Established thought leaders with verified media credentials.
The In Vivo Podcast, hosted by David Wild and Anabel Costa-Ferreira, explores the trends, innovations and strategies shaping global life sciences. Designed for biotech and pharmaceutical professionals, episodes feature journalists and industry leaders analyzing emerging technologies, R&D and market forces. Stay ahead with expert insight and intelligence. Visit https://insights.citeline.com/in-vivo for daily newsletters and life sciences commercial intelligence.
Norstella hosts In Vivo Podcasts, a business show with 8 episodes published.
On the heels of Eli Lilly recently committing $3.3bn across two recombinase-focused deals, the question for the field is which gene editing modality, and which delivery system, will get large genetic payloads safely into
Lyme disease is spreading, the last US vaccine was withdrawn in 2002, and the most recent attempt at a new one (Pfizer and Valneva's Phase III candidate) missed its primary endpoint earlier this year. Into that gap steps
This debut video episode of the In Vivo podcast examines the successes and pitfalls of the commercial launch of Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR-T therapy for relapsed/refractory large B-cell lymphom
This debut video episode of the In Vivo podcast examines the successes and pitfalls of the commercial launch of Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR-T therapy for relapsed/refractory large B-cell lymphom
AI, Philips, Healthtech, Future Health Index 2026
AI, Philips, Healthtech, Future Health Index 2026
GATC Health wants to give drug developers a “FICO score” for clinical risk. In this episode, David Wild talks with GATC chief business officer Tyrone Lam about Derisq, an AI‑driven report that simulates human biology to
GATC Health wants to give drug developers a “FICO score” for clinical risk. In this episode, David Wild talks with GATC chief business officer Tyrone Lam about Derisq, an AI‑driven report that simulates human biology to
A conversation with Jeremy Levin — physician-scientist, former Teva CEO, and author of Biotech and the Balance — on why America's biotech industry is at a strategic inflection point. Levin examines the forces undermining
A conversation with Jeremy Levin — physician-scientist, former Teva CEO, and author of Biotech and the Balance — on why America's biotech industry is at a strategic inflection point. Levin examines the forces undermining
Interventional cardiologist and Soley Therapeutics CEO Yerem Yeghiazarians joins In Vivo’s David Wild to unpack how decoding cell stress with live‑cell imaging and AI is driving a new oncology pipeline, and what it takes
Interventional cardiologist and Soley Therapeutics CEO Yerem Yeghiazarians joins In Vivo’s David Wild to unpack how decoding cell stress with live‑cell imaging and AI is driving a new oncology pipeline, and what it takes
Kurma Partners has closed BioFund IV at €215m — its largest fund to date, but roughly €35m short of its initial target. For partner Amanda Gett-Chaperot, that gap is more than a fundraising footnote: it points to a struc
Kurma Partners has closed BioFund IV at €215m — its largest fund to date, but roughly €35m short of its initial target. For partner Amanda Gett-Chaperot, that gap is more than a fundraising footnote: it points to a struc
Arcutis Biotherapeutics' CEO Frank Watanabe joins In Vivo’s David Wild to talk about building a patient‑first culture and turning a three‑person startup into a commercial‑stage immunodermatology company. He explains how
Arcutis Biotherapeutics' CEO Frank Watanabe joins In Vivo’s David Wild to talk about building a patient‑first culture and turning a three‑person startup into a commercial‑stage immunodermatology company. He explains how
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchShows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch In Vivo Podcasts, visit https://insights.citeline.com/in-vivo/ for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent business coverage.
In Vivo Podcasts is hosted by Norstella. The show is categorised under business and has published 8 episodes.
In Vivo Podcasts has published 8 episodes.
In Vivo Podcasts regularly covers business. It sits in the business category.
In Vivo Podcasts is accessible for guests with genuine business expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
In Vivo Podcasts hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of In Vivo Podcasts average 29 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates In Vivo Podcasts's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric.